Palisade Bio, Inc. (PALI)
NCM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Palisade Bio, Inc.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 500K |
| Operating Income | (2.9M) | (10.0M) | (10.7M) | (11.7M) |
| Net Income | (2.9M) | (8.9M) | (9.6M) | (10.6M) |
| Diluted EPS | $-0.38 | N/A | $-0.05 | $-0.05 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 250K | 0.00 | 0.00 |
| Operating Income | (15.3M) | (12.8M) | (14.9M) | (18.1M) |
| Net Income | (14.3M) | (12.3M) | (14.4M) | (16.8M) |
| Diluted EPS | $-247.95 | $-27.01 | $-10.19 | $-0.30 |